Overview

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about SP-420 ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia. The main questions it aims to answer are: - How efficient is SP-420 in cleaning iron from the liver? - How is the safety and tolerability of ascending doses of SP-420? Participants will: - Take medication three time weekly - Attend up to 20 site visits - Undergo MRI scans
Phase:
Phase 2
Details
Lead Sponsor:
Pharmacosmos A/S
Collaborator:
ICON plc